Clinical Trials Directory
This study has two parts. In the first part, researchers test different dose levels of a new medicine called BBO 11818 to find the safest and best dose. Some people will receive BBO 11818 by itself, while others will receive it together with other cancer medicines. The treatment group depends on the type of cancer and the specific KRAS gene change a person has. In the second part, more people will receive the dose that was found to be safe in the first part. Researchers will study BBO 11818 by itself and in combination with other treatments in different groups of patients. The goal is to learn more about how safe the medicine is, what side effects it may cause, and whether it can help slow or shrink cancers with specific KRAS gene changes.
Participants will complete various surveys about their health and experience with their new bowel program.
Right now, doctors do not have strong evidence to show which treatment is better, the sling (RP-MUS) or the gel (PAHG), when fixing vaginal prolapse and stress urinary incontinence at the same time. This study will give important information about how these treatments affect patients. This will help doctors and patients choose the best option.
The study has 4 parts: screening, taking the study drug, stopping the drug, and follow-up. You’ll get tests like blood work, heart checks, and scans. You’ll be randomly given one of two medicines: BGB-16673 or Pirtobrutinib, both taken once a day. After stopping the medicine, you’ll return for a check-up in about a month. If your cancer hasn’t gotten worse, you’ll visit every 6 months. If it has, the study team will check on you by phone or email. The whole study may last about 3 years with around 13 visits.
We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
We are doing this study to find out if an experimental drug called pegozafermin (the study drug) is a safe and effective option for people who have compensated liver cirrhosis due to MASH.